Invesco Launches India Pharma & Healthcare Fund NFO

Invesco Mutual Fund has introduced the Invesco India Pharma and Healthcare Fund, an open-ended equity scheme concentrating on the domestic healthcare sector. This New Fund Offer (NFO) is now available for subscription, targeting investors keen on India’s expanding healthcare demand.

Key Fund Details

• The NFO window for the fund runs from August 18 to September 1, 2026.
• The scheme aims to invest across the entire healthcare value chain, encompassing pharmaceuticals, hospitals, diagnostics, and medical devices.
• Aditya Khemani manages the fund, which is benchmarked against the BSE Healthcare Total Return Index (TRI).
• Minimum investment amounts are set at Rs 1,000 for a lumpsum contribution or Rs 100 for a Systematic Investment Plan (SIP).

The Invesco India Pharma and Healthcare Fund operates as a thematic offering, specifically designed to capitalize on growth opportunities within the Indian healthcare ecosystem. Its strategy involves a focused allocation across various sub-sectors to capture comprehensive industry expansion.

Risk Considerations

Investors should be aware that thematic funds inherently carry a higher risk profile due to their concentrated investment approach. Unlike diversified equity funds, this scheme focuses on a single sector, making it more susceptible to sector-specific volatilities.

The fund is generally suitable for individuals who already possess a diversified core portfolio, allowing for a strategic, higher-risk allocation. An exit load of 0.50% will be applied if units are redeemed or switched within three months of their allotment date.